IMU 0.00% 2.1¢ imugene limited

News: Imugene progressing cancer vaccine towards clinical studies

  1. Imugene (ASX:IMU) is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine, a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.

    Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.

    It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.

    Charles Walker, managing director. outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.

    The full presentation can be ACCESSED HERE.


watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Mkt cap $75.80M
Open High Low Value Volume
2.2¢ 2.2¢ 2.1¢ $39.07K 1.808M

Buyers (Bids)

No. Vol. Price($)
17 3836430 2.1¢

Sellers (Offers)

Price($) Vol. No.
2.3¢ 1621763 7
Last update - 16.10pm 11/12/2018 (20 minute delay) ?
0.00 ( 4.35 %)
Open High   Low Volume
2.2¢ 2.2¢   2.1¢ 1418020
Last updated 15.21pm 11/12/2018 (live) ?
IMU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.